Literature DB >> 12715241

Interference of anaesthetics with radioligand binding in neuroreceptor studies.

Betina Elfving1, Berith Bjørnholm, Gitte Moos Knudsen.   

Abstract

Evaluations of new emission tomography ligands are usually carried out in animals. In order to keep the animals in a restricted position during the scan session, anaesthesia is almost inevitable. In ex vivo rat studies we investigated the interference of ketamine/xylazine, zoletile mixture, isoflurane and halothane with the serotonin re-uptake site, the serotonin(2A) receptor and the dopamine re-uptake site by use of [(3)H]-(S)-citalopram, [(18)F]altanserin and [(125)I]PE2I, respectively. Ketamine/xylazine decreased the target-to-background ratio (mean +/- SD) of [(3)H]-( S)-citalopram from 1.5+/-0.19 to 0.81+/-0.19 (P<0.05), whereas isoflurane and halothane increased the ratio from 1.5+/-0.19 to 1.9+/-0.24 and 2.1+/-0.13 (P<0.05), respectively. Only with the zoletile mixture did the ratio remain unaltered. None of the tested anaesthetics affected the target-to-background ratio of [(18)F]altanserin. The [(125)I]PE2I target-to-background ratio decreased with both ketamine/xylazine (from 12.4+/-0.81 to 10.1+/-1.4, P<0.05) and isoflurane (from 12.4+/-0.81 to 9.5+/-1.1, P<0.05) treated rats, whereas treatment with zoletile mixture and halothane left the ratio unaltered. It is concluded that prior to performance of neuroreceptor radioligand studies, the possible interaction between radioligands and anaesthetics should be carefully evaluated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715241     DOI: 10.1007/s00259-003-1171-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  9 in total

1.  Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.

Authors:  T Poyot; F Condé; M C Grégoire; V Frouin; C Coulon; C Fuseau; F Hinnen; F Dollé; P Hantraye; M Bottlaender
Journal:  J Cereb Blood Flow Metab       Date:  2001-07       Impact factor: 6.200

2.  Evaluation of [O-methyl-(11)C]fluvoxamine as a tracer for serotonin re-uptake sites.

Authors:  P Wollmer; R M Moresco; P Simonelli; M Matarrese; M Rigamonti; G Ortu; R LaGaetana; D Soloviev; M Galli; F Fazio
Journal:  Nucl Med Biol       Date:  2000-02       Impact factor: 2.408

3.  Inhibition of 5-hydroxytryptamine type 2A receptor-induced currents by n-alcohols and anesthetics.

Authors:  K Minami; M Minami; R A Harris
Journal:  J Pharmacol Exp Ther       Date:  1997-06       Impact factor: 4.030

4.  Ketamine alters the availability of striatal dopamine transporter as measured by [(11)C]beta-CFT and [(11)C]beta-CIT-FE in the monkey brain.

Authors:  H Tsukada; S Nishiyama; T Kakiuchi; H Ohba; K Sato; N Harada
Journal:  Synapse       Date:  2001-12-15       Impact factor: 2.562

5.  The influence of isoflurane on the synaptic activity of 5-hydroxytryptamine.

Authors:  D C Martin; R J Adams; R S Aronstam
Journal:  Neurochem Res       Date:  1990-10       Impact factor: 3.996

6.  Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sites.

Authors:  T S Rao; P C Contreras; J A Cler; S J Mick; V M Dilworth; S Iyengar; J B Monahan; P L Wood
Journal:  J Neurochem       Date:  1991-03       Impact factor: 5.372

7.  Predosing with the unlabeled "inactive" enantiomer as a tool for improvement of the PET signal.

Authors:  Betina Elfving; Berith Bjørnholm; Gitte M Knudsen
Journal:  Synapse       Date:  2002-11       Impact factor: 2.562

8.  Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).

Authors:  D Guilloteau; P Emond; J L Baulieu; L Garreau; Y Frangin; L Pourcelot; L Mauclaire; J C Besnard; S Chalon
Journal:  Nucl Med Biol       Date:  1998-05       Impact factor: 2.408

9.  Anesthetics block morphine-induced increases in serotonin release in rat CNS.

Authors:  R Tao; S B Auerbach
Journal:  Synapse       Date:  1994-12       Impact factor: 2.562

  9 in total
  23 in total

1.  Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Vernon M Camp; Eugene J Malveaux; John R Votaw; Leonard Howell; Michael J Owens; Mark M Goodman
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

2.  Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.

Authors:  Masaki Tokunaga; Nicholas Seneca; Ryong-Moon Shin; Jun Maeda; Shigeru Obayashi; Takashi Okauchi; Yuji Nagai; Ming-Rong Zhang; Ryuji Nakao; Hiroshi Ito; Robert B Innis; Christer Halldin; Kazutoshi Suzuki; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

3.  Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Lauryn M Daniel; Ping Chen; Ronald J Voll; Larry Williams; Susan J Plott; John R Votaw; Michael J Owens; Leonard Howell; Mark M Goodman
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

4.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

5.  Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Authors:  Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2015-06-19       Impact factor: 3.641

6.  Propofol decreases in vivo binding of 11C-PBR28 to translocator protein (18 kDa) in the human brain.

Authors:  Christina S Hines; Masahiro Fujita; Sami S Zoghbi; Jin Su Kim; Zenaide Quezado; Peter Herscovitch; Ning Miao; Maria D Ferraris Araneta; Cheryl Morse; Victor W Pike; Julia Labovsky; Robert B Innis
Journal:  J Nucl Med       Date:  2012-11-12       Impact factor: 10.057

7.  [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot.

Authors:  Mohammed N Tantawy; Carrie K Jones; Ronald M Baldwin; M Sib Ansari; P Jeffrey Conn; Robert M Kessler; Todd E Peterson
Journal:  Nucl Med Biol       Date:  2009-10-03       Impact factor: 2.408

Review 8.  PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.

Authors:  Patrick Emond; Denis Guilloteau; Sylvie Chalon
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

9.  Reproducibility of non-invasive a1 adenosine receptor quantification in the rat brain using [(18)F]CPFPX and positron emission tomography.

Authors:  Tina Kroll; David Elmenhorst; Angela Weisshaupt; Simone Beer; Andreas Bauer
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

10.  Serotonin transporter binding and genotype in the nonhuman primate brain using [C-11]DASB PET.

Authors:  B T Christian; A S Fox; J A Oler; N T Vandehey; D Murali; J Rogers; T R Oakes; S E Shelton; R J Davidson; N H Kalin
Journal:  Neuroimage       Date:  2009-06-06       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.